Vomiting from Weight Loss Injections: Evidence, Causes and When to Get Help

What the clinical trials actually recorded about vomiting rates

The SURMOUNT-1 trial, published in the New England Journal of Medicine, enrolled 2,539 adults with obesity and tracked side effects across 72 weeks. Gastrointestinal events were the most common reason for discontinuation, and vomiting was reported by roughly one in five participants on the higher doses of tirzepatide, but the majority described it as mild or moderate, and rates dropped considerably once the body had adapted to each dose level. The picture was similar in the STEP 1 trial of semaglutide 2.4mg: GI side effects clustered around the titration steps rather than persisting throughout. That pattern is important. If you are several months into treatment and suddenly experience vomiting you had not had before, that is a different signal from the expected early adjustment and merits a conversation with your prescriber rather than waiting it out.

The NHS medicines information for tirzepatide confirms that nausea, vomiting, diarrhoea and constipation are common effects, and that they tend to be most pronounced after a dose increase. You can read that detail on the NHS tirzepatide medicines page, which is a reliable first reference for patient-level information.

Why these injections cause vomiting, and what that means practically

Tirzepatide and semaglutide slow the rate at which the stomach empties its contents, a mechanism that contributes to reduced appetite and calorie intake, but also means the stomach is fuller for longer. When the system is adjusting to a new dose, that delay can tip into nausea and, for some people, vomiting. Eating smaller portions, chewing slowly and avoiding high-fat or strongly spiced foods in the early weeks after a dose step tends to reduce the severity. A practical check worth doing in under a minute: before your injection day, note what you ate in the hour before your last nausea episode, a pattern of large evening meals or fatty takeaways often emerges, and avoiding those foods around injection day can make a real difference.

Injection timing and technique also play a role. Our clinical team page has background on how prescribers at nume approach dosing decisions, and if you want an overview of how these medicines work across the weight management landscape, the weight loss injections overview sets out the options clearly. It is also worth reading about injecting insulin for weight loss, which explains how injectable treatments compare and why GLP-1 medicines have become the preferred clinical route for most people.

When vomiting becomes a medical emergency, not a side effect to manage at home

The MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis as a known, infrequent but serious risk with GLP-1 medicines. The key warning sign is severe stomach pain that reaches into the back, with or without vomiting, this combination should prompt you to stop the injection and get urgent medical help, not to wait and see. Separately, sustained vomiting lasting more than 24 hours raises the risk of dehydration serious enough to affect kidney function, and this is the category that most commonly requires hospital assessment. Signs that dehydration is becoming significant include markedly reduced urination, feeling faint when standing, or urine that is dark amber rather than pale. If you experience any of these alongside vomiting, contact NHS 111 or attend an urgent care centre promptly.

Other situations that need medical review rather than home management include vomiting that begins weeks into a stable dose with no obvious dietary trigger, vomiting accompanied by yellowing of the skin or eyes, and any episode so severe that you cannot keep fluids down for several hours. You can report any suspected side effect directly via the MHRA Yellow Card scheme, doing so helps regulators monitor emerging patterns in the real-world population using these medicines.

Practical steps, and how our prescribers approach this with patients

If vomiting is disrupting your treatment but does not meet the urgent-help criteria above, the right move is to contact your prescriber before making any changes. Adjusting the timing of your injection, holding a dose increase longer, or reviewing whether a missed dose has affected your routine are all decisions that need clinical input, they are not things to navigate alone using general advice online. The weight loss injection guide covers how these treatments work in practice, including what to expect at each stage of your programme, but personalised guidance on managing your dose is always a prescriber conversation.

For people who have found the injectable route difficult to tolerate, it is worth knowing that the landscape of weight loss treatment options has expanded. An oral GLP-1 medicine (Wegovy tablets) was approved by the MHRA in June 2026, though it is not without its own GI side-effect profile. Separately, there is useful background on the broader three main weight loss injections available in the UK for anyone comparing routes, and our weight loss injections prices page sets out what each option costs so you can factor that into your decision. Exploring what is right for you starts with a clinical assessment, not a Google search. Our prescribers discuss side effects, including vomiting, as a standard part of every consultation, and if you are specifically considering the weight loss injection starting with t, our team can walk you through its side-effect profile and whether it suits your circumstances. If you would like that conversation, you can start your free consultation with our team. There is no commitment, and your answers are reviewed the same day by a real prescriber, not automated software.